Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Reference-Cited by-同舟云学术

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Published:2021-03-01 Issue:3 Volume:7 Page:386
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Akamatsu Hiroaki¹,Toi Yukihiro²,Hayashi Hidetoshi³,Fujimoto Daichi⁴,Tachihara Motoko⁵,Furuya Naoki⁶,Otani Sakiko⁷,Shimizu Junichi⁸,Katakami Nobuyuki⁹,Azuma Koichi¹⁰,Miura Naoko¹¹,Nishino Kazumi¹²,Hara Satoshi¹³,Teraoka Shunsuke¹,Morita Satoshi¹⁴,Nakagawa Kazuhiko³,Yamamoto Nobuyuki¹

Affiliation:

1. Internal Medicine III, Wakayama Medical University, Wakayama, Japan

2. Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan

3. Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan

4. Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan

5. Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan

6. Division of Respiratory Medicine, Department of Internal Medicine, St Marianna University School of Medicine, Kanagawa, Japan

7. Department of Respiratory Medicine, Kitasato University School of Medicine, Kanagawa, Japan

8. Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan

9. Department of Medical Oncology, Department of Pulmonary Medicine, Chemotherapy Center and Division of Clinical Research, Takarazuka City Hospital, Hyogo, Japan

10. Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan

11. Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

12. Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan

13. Department of Respiratory Medicine, Itami City Hospital, Hyogo, Japan

14. Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2774521/jamaoncology_akamatsu_2021_oi_200101_1615397480.54429.pdf

Reference24 articles.

1. Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival.;Lee;J Natl Cancer Inst,2017

2. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.;Sequist;J Clin Oncol,2013

3. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.;Sequist;Sci Transl Med,2011

4. Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development.;Yver;Ann Oncol,2016

5. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.;Mok;N Engl J Med,2017

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimerinib haematological toxicities in non-small cell lung cancer: a randomised controlled trials meta-analysis;BMJ Supportive & Palliative Care;2024-08-19

2. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial;Signal Transduction and Targeted Therapy;2024-08-13

3. Diffusion weighted MRI and apparent diffusion coefficient as a prognostic biomarker in evaluating chemotherapy-antiangiogenic treated stage IV non-small cell lung cancer: A prospective, single-arm, open-label, clinical trial (BevMar);European Journal of Radiology;2024-08

4. eHSP90α in front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced lung adenocarcinoma;BMC Cancer;2024-07-12

5. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11